Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

« Older Entries
Newer Entries »

Namaste $N.ca $NXTTF and Phivida $VIDA.ca Announce Exclusive Supply Agreement $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:18 AM on Thursday, January 11th, 2018

Nlogo

  • Announce that it has signed a Global Digital Reseller-Supply Agreement with Phivida Holdings Inc.
  • Namaste has been approved as the preferred global online retailer and digital affiliate marketing partner for Phivida’s product line of premium hemp-derived Cannabidiol infused functional beverages and clinical health products

VANCOUVER, British Columbia, Jan. 11, 2018 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce that it has signed a Global Digital Reseller-Supply Agreement (the “Agreement”) with Phivida Holdings Inc. (“Phivida”) (CSE:VIDA), (OTCMKTS:PHVAF).

As key terms in the agreement, Namaste has been approved as the preferred global online retailer and digital affiliate marketing partner for Phivida’s product line of premium hemp-derived Cannabidiol (“CBD”) infused functional beverages and clinical health products. The agreement includes a global online territory, targeting the launch in Germany and Australia (the “Territories”).

Phivida CBD beverages, extracts, juices and shots are professionally formulated by health care practitioners, made with premium ingredients, tested for quality, safety and manufactured to GMP standards. This Agreement represents a strategic initiative between both companies to promote high quality CBD products through Namaste’s platform and to the Company’s existing databases of users within the Territories. CBD is a cannabinoid compound which can be derived from both cannabis and hemp plants and plays a vital role in the emerging global medical cannabis market.

With Phivida’s management team having a strong background from the beverage industry and branding, including former senior executives from Redbull, Proctor and Gamble and McKesson’s, Namaste is pleased to be able to offer Phivida’s premium CBD beverages and infusions to its patients and practitioners globally, with an initial launch in Australia and Germany.

Terms of the Agreement

  • Namaste has exclusive rights for online retail of Phivida’s products in the Territories
  • The Agreement is valid for a 24-month period
  • The Agreement payment terms are net 30 days
  • Namaste shall be responsible for delivery costs
  • Namaste will under no circumstance retail PHIVIDA products for a price that is less than the regular retail price at which the products are advertised on PHIVIDA’s website
  • The Agreement states that all online product marketing expenses within the Territories will be shared equally between PHIVIDA and Namaste
  • The Agreement is subject to obtaining a legal opinion from a designated legal firm, agreed to by both parties

Namaste’s globally diversified network of e-commerce sites and distribution centers will allow Namaste, in its partnership with Phivida, to reach users in new and emerging medical cannabinoid based medical and consumer health markets. This Agreement further represents Namaste’s commitment to deploy its strategic initiatives in an effort to bring the most innovative products to market. Namaste’s growing global database of consumers continues to provide value to the Company and its partners, as it aims to leverage its technical expertise relating to its cutting-edge SEO and machine learning technologies.

This Agreement represents a pilot project between both companies whereby Namaste will distribute Phivida’s proprietary CBD beverages and infused products within the designated territories. Both companies intend on further expanding distribution through other markets where Namaste maintains significant market share.

While the Canadian market remains a primary focus for Namaste, it has identified additional opportunities in the Australian and German markets, as both countries continue to demonstrate a keen willingness to move closer towards full legalization. This partnership will allow Namaste to transition seamlessly into both markets, as it looks to broaden the scope of the products and services it provides. This Agreement represents an important step for Namaste as it looks to expand its presence into emerging markets and believes Phivida’s CBD beverages, oils and infusions offer Namaste an incredible opportunity to expand its offering globally.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “Namaste is extremely excited to be partnering with Phivida and its world-class management team. We’re looking forward to entering the beverage space together with Phivida as we believe there is significant demand for these products in our market. Many of our successes to this point can be largely attributed to our keen ability in identifying industry leaders and then forming strategic alliances.  Our partnership with Phivida further demonstrates that ability, and we feel very optimistic to be collaborating with a management team whose pedigree speaks for itself.   We would like to thank Phivida for granting Namaste rights of its online retail products in the Territories, as we expand our presence globally.

We fully expect this partnership to evolve and fully intend on exhausting all opportunities whereby both parties are able grow and expand their respective market share. Not only does this offer Namaste the ability to expand its product line but so too does it help us in penetrating new markets as we look to create the world’s most expansive online medical cannabis marketplace.”

John – David Belfontaine, President and CEO of Phivida reports: “As Phivida continues to expand is CBD product offerings into a $1 Trillion global health and wellness marketi, it is critical that we secure the strongest distribution partners. Ecommerce and digital marketing is a core horizontal within our greater strategic business plan, and Namaste is an ideal partner to expand our online presence into emerging markets around the world. We look forward to launching our global digital marketing and distribution platform with Namaste’s support as a key strategic partner.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

About Phivida 
Phivida [“fiii-vee-daa”] is a publicly traded company listed on the Canadian Securities Exchange under the ticker symbol “VIDA”. Phivida is a premiere brand of cannabidiol (“CBD”) infused functional foods, beverages and clinical health products, poised for global distribution. Using nanoencapsulation technology, Phivida converts lipid based cannabinoids into water soluble delivery format, enhancing bioavailability, and timed released within the body. Phivida’s nanoencapsulated CBD is infused into CBD beverages, foods and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health conditions, from chronic pain to terminal diseases. Phivida Enhanced Inc. (a wholly owned subsidiary of Phivida Holdings Inc.) is the clinical division of Phivida responsible for the formulation, manufacturing and distribution of the professional line clinical products under the brand name Vida+. These clinical grade CBD products include sublingual’s, hard capsules and other full spectrum CBD-hemp oil extract infused nutraceuticals and natural health products. The Vida+ label is a professional line of products clinical grade for higher potency and are third party laboratory tested for cannabinoid potency, terpenes, residual solvents, bacteria and pesticides.  Celebrating; Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as the benchmark quality standard in premium cannabinoid infused foods, beverages and clinical products, with a dedication to research, education and investing back into the communities that we so proudly serve.

For investor relations inquiries and updates, please contact Phivida via the information listed below.

Website www.phivida.com  Toll free +1 (844) 744-6646 (ext. #2)  E-mail [email protected]     Twitter  https://twitter.com/Phivida Facebook                                  https://www.facebook.com/phivida YouTube  https://www.youtube.com/watch?v=YqvHSMbhKwQ&t=7s

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk

i https://blog.euromonitor.com/2012/11/health-and-wellness-the-trillion-dollar-industry-in-2017-key-research-highlights.html

Tags: , ,
Posted in Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF and Phivida $VIDA.ca Announce Exclusive Supply Agreement $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca Announces Services Agreement With #Cannamerx Cannabis Mercantile Exchange $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:23 AM on Tuesday, January 9th, 2018

Nlogo

  • Announced that it has entered into a Services Agreement with Cannamerx;
  • Canada’s first online marketplace for the wholesale purchase of medical cannabis certified under the Access to Cannabis for Medical Purposes Regulations
  • All bids submitted over the platform are binding;
  • Sale transactions are Ex Works;
  • Cannamerx offers strong buyer protection to ensure products match descriptions;

VANCOUVER, BRITISH COLUMBIA, Jan. 09, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N)(FRANKFURT: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that it has entered into a Services Agreement (the “Agreement”) with 3955 Trading Inc. (“Cannamerx”), Canada’s first online marketplace for the wholesale purchase of medical cannabis certified under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). Cannamerx is a fully automated, ACMPR-compliant forward auction trading platform for bulk cannabis and cannabis products in Canada. Developed in close collaboration with Canadian licensed producers, Cannamerx is designed to facilitate the trade of bulk cannabis and cannabis products between licensed producers throughout the country. Namaste believes that Cannamerx’s platform will offer strategic benefits to the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”), which is a late stage ACMPR applicant for a medical cannabis “sale-only” license. Through Cannmart, Namaste will create an online retail marketplace for medical cannabis that will offer the largest variety of products sourced from ACMPR licensed producers as well as international cultivators.

Terms of the Agreement:

  • All bids submitted over the platform are binding;
  • Sale transactions are Ex Works;
  • Cannamerx offers strong buyer protection to ensure products match descriptions;
  • Cannamerx ensures that all ACMPR compliant;
  • Cannamerx is strictly a business to business marketplace;
  • Cannamerx does not charge sign-up or listing fees;
  • Cannamerx does not charge any buyer commission;
  • Bidding on Cannamerx is anonymous; and
  • The Agreement is non-exclusive to Cannmart.

Using the Cannamerx platform will enhance Namaste’s ability to efficiently source cannabis and cannabis products from small-scale licensed producers throughout Canada, creating a diverse product selection for Cannmart’s online marketplace customers.  While large licensed producers will continue to play a vital role in Namaste’s distribution, the Company believes that the Agreement will allow the Company to connect customers with the craft cannabis market, an important niche market that could experience significant growth similar to the craft beer and wine industries.

In addition to the announcement of the Agreement, Namaste would like to announce that Mr. Clifford Stark will be leaving Namaste’s board of directors in pursuit of a new business venture. Mr. Stark has provided Namaste with valuable advice and insight during his position as an active board member of Namaste’s team. The Company would like to thank Mr. Stark for his service and wishes him best of luck in his future endeavors.

Management Commentary
“We are proud to welcome Namaste to Cannamerx,” said Dietwald Claus, CEO of 3955 Trading Inc., which owns and operates Cannamerx. “We developed Cannamerx to provide Canadian licensed producers with an effective, easy-to-use, ACMPR-compliant platform for the trade of wholesale cannabis and cannabis products in Canada. By bringing together licensed producers, processors, and retailers from across the country on a single trading platform, we anticipate that Cannamerx will play a critical role in growing a diversified and robust Canadian cannabis industry. Namaste’s decision to join Cannamerx is a strong vote of confidence in our technology and business model. We look forward to welcoming more participants over the coming months as Canada prepares to legalize recreational cannabis.”

Sean Dollinger, President and CEO of Namaste comments, “This Agreement represents a unique opportunity for both parties, as we look for new ways to increase the appeal of our online marketplace. Our relationship with Cannamerx is not intended to replace our existing supply channels, but rather to broaden the selection of quality cannabis products that we are able to provide to our customers. Namaste believes Cannamerx fits well with our purchasing strategy moving forward, and we anticipate Cannamerx playing a significant role in helping us access cannabis from smaller licensed producers to supply Canadian consumers with the most diverse selection in a cannabis space.”

“In addition to the benefits Cannamerx provides Namaste, we believe Cannamerx provides a great channel for licensed producers looking to wholesale their cannabis. Namaste is committed to providing Canadian cannabis users with easy access to the widest range of cannabis products and this agreement helps fast track our efforts in achieving those goals.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Tags: , ,
Posted in Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Services Agreement With #Cannamerx Cannabis Mercantile Exchange $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Canadian #cannabis producers set their sights on global domination $N.ca $TBP.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 11:10 AM on Friday, January 5th, 2018

  • Medical research forcing an end to prohibition
  • “I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.
  • In recent months, more than a dozen countries have legalized medical marijuana

Medical marijuana consumers in Prague rang in 2018 with a new Canadian import, Tilray Milled Cannabis, a high THC marijuana product grown on Vancouver Island.

The Czech Republic is just the latest nation to sell Canadian weed, joining Germany, Australia, New Zealand and a growing list of other nations which are turning to Canada as a safe and legal source for medical grade cannabis.

In recent months, more than a dozen countries have legalized medical marijuana. New laws are pending in at least a dozen more as national regulators and even the World Health Organization recognize legitimate medical uses for a drug which had long been banned under international treaties.

The moves have sparked an unprecedented demand for legally grown, high quality marijuana, as well as the oil which is extracted from it. Seven Canadian producers have been granted licences to export the crop. By the end of March they will have sent 528 kilograms of dried cannabis flower and 911 litres of oil overseas. That may well be just an initial trickle, as the floodgates open on an international medical cannabis market.

“I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.

Brendan Kennedy of Tilray says Canada is the source of the safest product when regulators in other countries go looking for medical marijuana. (Evan Mitsui/CBC)

“I think it means that we’ll be a global player,” he says, stressing this is a positive development for the Canadian economy. “This could be our opportunity to be viewed the same as we are in mining or hockey. We’ll be world class and be world leaders and I think that will stay to be the case for a very, very long time.”

Medical research forcing an end to prohibition

For decades an international ban on the production and use of cannabis kept to a minimum any legitimate research into potential medical uses. Prohibition ensured that marijuana cultivation stayed in the hands of illegal growers, and distribution was limited to the criminal underground.

But many users saw value in cannabis as treatment for a variety of conditions, ranging from controlling epileptic seizures to pain relief to stress control.

Israeli scientist Raphael Mechoulam began limited research on the drug in the early 1960s, which led to the discovery of the human endocannabinoid system. By the mid-1990s, scientists determined that cannabinoid receptors play a vital role in the function of the human body. For the first time synthetic cannabinoid derivatives were approved for medical use, primarily for the treatment of nausea and wasting syndrome.

At the same time anecdotal evidence was building to suggest cannabis could have other, more widespread medical uses. Patients who claimed benefits from cannabis went to court seeking the right to use marijuana as medicine without facing the risk of criminal prosecution.

In 2000 the Ontario Court of Appeal ruled that Terry Parker, a man with severe epilepsy, should have the right to use marijuana to moderate his severe seizures.

One year later, Canada’s Medical Marijuana Access Program was introduced, allowing patients who had obtained a doctor’s consent to grow their own marijuana under a special permit. By 2013 more than 28,000 Canadians had been granted personal use production licences, leading to a flood of unregulated home-grow operations, and along with it a risk of fires, mould contamination in homes, and legally grown weed being diverted to the black market.

In an effort to crack down on the home grow-ops, the Harper Conservative government introduced new legislation that established legal grow operations which could provide medical marijuana through a mail order service. The Marijuana for Medical Purposes regulations, enacted in 2014, set Canada apart as the first nation to establish a regulated commercial cannabis cultivation industry.

Canadian pot finds a role in the world market

As Canada moves towards legal recreational weed in July, the number of licensed growers has swelled to 84, production is skyrocketing, and research into new growing techniques and improved strains is increasing exponentially. This has placed Canada in a unique role as other nations scramble to find safe and legal supplies of medical cannabis.

Cam Battley, executive vice president of Aurora, shows off Aurora Vie’s Pointe-Claire, Que., facility. Canadian producers have expertise in greenhouse technology, extraction methods, strains and genetics. (CBC)

“When regulators in other countries are looking for a product, Canada is really the source of the safest product. It’s the safest bet,” explains Brendan Kennedy, the CEO of Nanaimo-based Tilray, a pioneer in cannabis exports.

Tilray is among several Canadian producers already exporting to Germany, which established a widespread marijuana access program last spring. Not only is cannabis stocked in German pharmacies, the government pays for the drug under its government health insurance program.

Until it can establish a domestic industry, Germany is importing from Canada. Along with Tilray, Canadian producers Aurora, Cronos and Canopy Growth are tapping the German market. Aurora has even gone a step further, purchasing pharmaceutical supplier Pedanios, with an eye to expanding its distribution in the European market.

Following Germany, several other European countries, including Greece, Italy, Poland and the Czech Republic, passed new medical cannabis laws. Several others are following. A report published in November places the value of the European cannabis market at $84 billion Cdn a year.

That’s led Tilray to begin construction of a $30-million production facility in Portugal to help supply the growing market.

Beyond exports, Canada has expertise

“Part of the reason we decided to invest in a cultivation facility in Portugal was that we also saw a massive increase in demand for medical cannabis product in the EU,” explains Kennedy, who sees a bright future well beyond Canadian exports.

Canadian expertise in growing and greenhouse technology, extraction methods, strains and genetics, along with plain old business know-how, are also in demand. In addition to exports, Canada’s cannabis companies are also teaming up with local partners to build facilities in Germany, Denmark and Israel.

Australia is seen as another prize for Canadian producers. When it announced last February that it would allow importation, Canadian producers Aurora, CannTrust, Canopy, MedReleaf and Tilray swooped in, not only with bags of weed and vials of oil, but with partnerships to build facilities there.

Peru and Mexico have also passed legislation to legalize medical cannabis, and Canadian companies are promising further announcements soon. Overall, they say, the world market could be worth around $200 billion.

What it all means

The rapid legalization of medical cannabis has spurred new research into potential treatments using the drug. In Israel, where the medical research began, there are about 120 trials underway using components of the marijuana plant.

Neil Closner, CEO of Ontario-based MedReleaf, believes Canadian medical marijuana producers have the potential to become global giants. (Canadian Press)

As cures and treatments are discovered and proven, the role of cannabis is sure to expand, creating even greater potential beyond flowers and oil. CEO of Markham-based MedReleaf Neil Closner believes at least two or three of Canada’s producers will become global giants.

“I think overall who wins is Canada. I think we’ve got a leg up on the rest of the world, which is very exciting at a national level for us. I’d like to think that MedReleaf is strongly positioned to be one of the few handfuls of global winners.”

And while California is the latest U.S. state to legalize marijuana, American producers are shut out of the global market because of the federal prohibition on the drug.

That leaves Canada room to pursue the international market and all the potential riches that go with it.

Source: http://www.cbc.ca/news/business/medical-marijuana-canadian-export-1.4470407

Tags: , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on Canadian #cannabis producers set their sights on global domination $N.ca $TBP.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Live 420 Stream: Latest Press Releases | Aurora Cannabis $ACB.ca – Live Today At 4.20pm EST

Posted by AGORACOM-JC at 4:05 PM on Wednesday, January 3rd, 2018

Tags: , , , , , ,
Posted in Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Live 420 Stream: Latest Press Releases | Aurora Cannabis $ACB.ca – Live Today At 4.20pm EST

Marijuana Company of America’s $MCOA Overview of 2017 Highlights $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:47 AM on Wednesday, January 3rd, 2018

15233 mcoa

2017 HIGHLIGHTS

  • MCOA became a fully reporting company by filing a Form 10 with the SEC in May of 2017
  • In Q1 2017, MCOA entered into a joint venture partnership with Bougainville Ventures, Inc
  • In Q3 2017, MCOA and Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) entered into a joint venture partnership to develop commercial hemp production and processing in New Brunswick
  • In October 2017, MCOA and GHG jointly entered into a letter of intent  with Space Cowboys, Inc.

Escondido, California–(January 3, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce its 2017 year-end review to its valued shareholders and interested parties.

Donald Steinberg, CEO of MCOA, said: “I am the founder of multiple startups, including Medical Marijuana Inc. (OTC: MJNA), which has a market cap of over 300 million dollars. I am aware of the challenges and opportunities these endeavors present, and the need for a strong foundation to build upon. Having experience in the structuring, development and operations of large global marketing companies in various industries, I believe Marijuana Company of America and its subsidiary hempSMART are poised to deliver significant value to our shareholders based on the foundations and accomplishments made in the past year. 

The Company has fulfilled its promise to its shareholders by becoming an audited and fully transparent reporting company with the Securities and Exchange Commission. We are participating in the cannabis space with our leasing operation in Washington. The hempSMART team has developed a line of products that can be viewed at www.hempsmart.com. We completed joint hemp trials in New Brunswick, Canada with Global Hemp Group, Inc. in 2017, and we expect to be starting commercial production in Spring 2018. There are a number of other projects we are completing due diligence on. I am thankful to the teams at MCOA and hempSMART for their accomplishments and due diligence in working through these various projects.  We will continue to build upon the diligent work of the past year as we continue to move forward and execute our business plan.”

Updates on hempSMART Products

The Company’s wholly owned subsidiary, hempSMART, Inc., distributes industrial hemp based CBD wellness products via network marketing. In September 2017, the Company completely revamped its website and network marketing platform to provide customers and affiliates with the necessary tools needed to become successful in the expanding $1.9 Trillion Wellness Industry. The Company has successfully filed a patent application with the U.S Patent and Trademark Office for full patent protection on its proprietary CBD formulation: “hempSMART™ Brain.” Also in 2017, hempSMART released two new products: “hempSMART™ Full Spectrum Drops” (Orange, Mint, Lemon, and Strawberry) and “hempSMART™ Pain Capsules.” Several more products are in development and the Company anticipates their release in Q1 2018.

Filing Form 10 with SEC and Completing Audit

MCOA became a fully reporting company by filing a Form 10 with the SEC in May of 2017. A PCOAB registered audit firm (L & L CPAs PA) completed a two-year audit of the Company’s 2015 and 2016 financial statements. This is an integral step to qualifying the Company to uplist its trading tier with OTC Markets to the OTCQB. This is an important step in helping MCOA raise necessary capital to fund it projects and expand operations, as well as provide more transparent and reliable information to investors. Currently, the Company is in the process of preparing and filing an S-1 registration statement with the SEC in order to raise the necessary capital to fund its aggressive growth goals for 2018. Due to the inherent legal complexity of the cannabis industry, it took considerable effort to address SEC comments pertaining to disclosures of our business and corresponding products. We believe there is a great deal of shareholder value by the Company distinguishing itself from a majority of cannabis public companies that elect not to be fully reporting SEC filers.

Cultivation Joint Venture in Washington State

In Q1 2017, MCOA entered into a joint venture partnership with Bougainville Ventures, Inc. (“BV”), who plans to construct a 30,000 sq. ft. greenhouse cultivation facility in Oroville, WA. The facility will accommodate a Tier-3 production and processing I-502 tenant with years of experience in cannabis cultivation. In Q4 of 2017, MCOA completed financing of $800,000 in cash and 15 million shares of the Company’s common stock to complete the amended terms of the agreement. The delivery of the first pre-designed greenhouses, with full tracking and reporting protocols has arrived and completed construction of the six greenhouses, totaling in a one-acre footprint, is expected in Q1 2018. This joint venture project is solely for the purpose of cultivation and processing of legal marijuana within the state of Washington only and not beyond its borders. The Company will lease the turnkey property to the licensed tenant, thus acting solely as a landlord. As of December 31, 2017, the first greenhouse was purchased and in the process of being constructed.

JV with Global Hemp Group in Canada

In Q3 2017, MCOA and Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) entered into a joint venture partnership to develop commercial hemp production and processing in New Brunswick, Canada. MCOA and GHG have now completed the first phase of hemp trials, receiving research support from the Collége Communautaire du Nouveau Brunswick (CCNB). MCOA is granted a Right of First Refusal as the primary recipient of any raw materials produced from the project, which we expect will harvest its first commercial crop of 125 acres in Q4 2018.

MoneyTrac Technologies Investment

In July 2017, MCOA completed an investment of $250,000 into MoneyTrac Technology, Inc. (“MTT”), a subsidiary of Global Payout, Inc. (OTC: GOHE) in exchange for 15% equity position in the company, to help establish and market MTT as an alternative banking solution for the Cannabis industry. MTT currently has the ability to integrate and streamline electronic payment processing such as E-wallet, mobile applications, debit cards, and credit cards. Currently, MoneyTrac Technology has strategic partnerships with top cannabis services such as GreenRush, BlazeNow, High Grade Management Group, and PotSaver, which was a majority acquisition last October.

BeniHemp Investment

At the end of Q4, the Company announced an investment of $100,000 for a 25% equity stake in Convenient Hemp Mart, LLC’s “BeniHemp” branded products to target convenience stores for CBD product distribution. BeniHemp products will include topicals, tinctures, and edibles conveniently packaged in 1-day, 2-day, and 30-day supplies. The target market is convenience stores, smoke shops, gas stations and similar small retail businesses. The expectation is that there will be a full launch and website online in January 2018.

Space Cowboys, Inc.

In October 2017, MCOA and GHG (“the Companies”) jointly entered into a letter of intent (LOI) with Space Cowboys, Inc. (“Space Cowboys“). Pursuant to the terms of the LOI, the Companies intended to invest US$2.5 Million in exchange for a 25% equity interest in Space Cowboys. However, the Companies are unable to complete due diligence and will not be moving forward with this project.

Joint Venture in Adelanto, CA

In March, MCOA entered into a joint venture agreement with GateC Research Inc. (“GCR”) for the purpose of developing a turnkey cultivation facility in Adelanto, California for leasing to GCR which owns a local permit for cultivation. GCR and MCOA are in the process of identifying and securing property to facilitate the project. MCOA will invest cash and stock to complete the agreement. With the recent legalization of cannabis for recreational use on January 1, 2018 in California, MCOA expects to focus its attention on actualizing this opportunity in California. This JV project is solely for the purpose of cultivation of legal marijuana within the state of California and not beyond its borders. The Company will act solely as a landlord in this JV.

Investor Relations

Also in 2017, MCOA engaged NetworkNewsWire (“NNW”) for the Company’s corporate communication solutions. NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with MCOA, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About MoneyTrac Technology
MoneyTrac Technology, Inc. is a pioneer in offering a full-service solution for alternative banking and electronic financial solutions and provides all aspects of financial technology including E-Wallet and mobile apps services for businesses and companies in various “high-risk” industries. MoneyTrac’s technology platform allows for its clients to access their financial information from anywhere in the world, in addition to providing tracking and compliance to help them manage and control the flow of all revenue through their business.

About Global Hemp Group Inc.
Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and establish a greater collective valuation.

About Bougainville Ventures, Inc.
Bougainville Ventures Inc. is in the business of investing in high grow companies and industries that lease land, equipment and other growing infrastructure to licensed marijuana producers and luxury crop growers. Bougainville itself is not a licensed marijuana grower or retailer but instead focuses on providing capital to companies which act as landlords and equipment leasing companies to licensed marijuana producers and luxury crop growers. The Company is in the process of being listed on the CSE in Canada.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Tags: , , , , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America’s $MCOA Overview of 2017 Highlights $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary $AERO $CBDS $CGRW $APH.ca $GBLX #CBD #Marijuana

Posted by AGORACOM-JC at 9:13 AM on Tuesday, January 2nd, 2018

Logo tetrabiopharma rgb web

  • Announced that it has entered into a share purchase agreement  with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation
  • Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc.

OTTAWA, ONTARIO–(Jan. 2, 2018) Tetra – Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement“) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors“).

Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc. (“PPP“), currently held by the Vendors (representing 20% of the issued and outstanding shares of PPP) for an aggregate purchase price (the “Purchase Price“) of $12,425,089 (the “Transaction“). Upon completion of the Transaction, PPP will become a wholly-owned subsidiary of Tetra.

“Upon completion, this transaction will be a significant milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO.

“The two selling shareholders – our Chairman and our Chief Scientific Officer – are both committed to the long-term success of Tetra as evidenced by their agreement to accept shares in Tetra in lieu of an all- cash transaction. As well, a percentage of those shares are going to be released once certain key milestones for the company have been reached,” he said.

“This transaction will allow Tetra to gain 100% control of Phytopain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives our company full flexibility to enter into other partnerships or agreements in the future.”

The Transaction is subject to customary closing conditions including, but not limited to, approval of the TSX Venture Exchange (“TSXV“) and any other approval that may be required by the TSXV.

The Transaction

Under the terms of the Purchase Agreement, the Purchase Price for the Transaction is comprised of the following:

  • Cash: An aggregate cash payment of $248,000 (the “Cash Payment“). Under the terms of the Purchase Agreement, the Cash Payment is payable in escrow as of the signature of the Purchase Agreement and has been paid to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV. In addition, Tetra has agreed to pay the Vendors, immediately upon signature of the Purchase Agreement, a non-refundable amount of $200,000, payable out of the funds available for the Cash Payment, to induce the Vendors to provide an exclusivity of negotiation to the Purchaser for the Transaction.
  • Promissory Notes: Promissory notes issued by Tetra to the Vendors in an aggregate principal amount of $2,236,696 (the “Notes“), which Notes are payable in accordance with a specified milestone schedule as described in the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the Notes have been delivered to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV.
  • Tetra Shares: Common shares of Tetra (“Common Shares“) will be issued to the Vendors as follows:
    • Upon completion of the Transaction, an aggregate of 2,485,218 Common Shares will be issued to the Vendors.
    • Upon completion of the Transaction, 7,455,653 Common Shares will be issued to
      Computershare Trust Company of Canada, as escrow agent (the “Escrow Agent“), to be held in escrow and released by the Escrow Agent under the terms and conditions set forth in the Purchase Agreement and the terms and conditions of an escrow agreement to be executed at closing by the Vendors, the Corporation and the Escrow Agent.

The Vendors under the Purchase Agreement are entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation and are therefore considered “non-arm’s length parties” under the rules of the TSXV. Mr. Rancourt and Mr. Chamberland have properly disclosed their respective interest in the Transaction to the board of directors of the Corporation.

The Transaction constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). While MI 61-101 would generally subject the transaction to minority shareholder approval and formal valuation requirements, the Corporation will avail itself of the exemptions applicable under Section 5.5(a) of MI 61- 101.

Mr. Rancourt currently has ownership or direction and control over (i) an aggregate of 465,000 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 0.37% of the issued and outstanding Common Shares on a non- diluted basis and approximately 4.66% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Rancourt are released to Mr. Rancourt or an affiliate of Mr. Rancourt in accordance with the Purchase Agreement, Mr. Rancourt would then have ownership or direction and control over (i) 5,435,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.20% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.17% of the issued and outstanding Common Shares.

Mr. Chamberland currently has ownership or direction and control over (i) an aggregate of 1,250,000 Common Shares, (ii) 350,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 1.00% of the issued and outstanding Common Shares on a non-diluted basis and approximately 4.32% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Chamberland are released to Mr. Chamberland or an affiliate of Mr. Chamberland in accordance with the Purchase Agreement, Mr. Chamberland would then have ownership or direction and control over (i) 6,220,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.78% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.70% of the issued and outstanding Common Shares.

Each of Mr. Rancourt and Mr. Chamberland proposes to acquire the common shares for investment purposes, and has no current intention to increase his beneficial ownership of, or control or direction over, securities of Tetra. These investments will be reviewed on a continuing basis and their holdings may be increased or decreased in the future.

The Transaction is subject to customary conditions including, but not limited to, approval of the TSXV. The Transaction has been unanimously approved by Tetra’s board of directors (with André Rancourt abstaining from voting) and Tetra anticipates that the Transaction will be completed in the first quarter of 2018.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Corporation, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Bernard Fortier, MBA
Chief Executive Officer
(514) 360-8040 Ext. 206
[email protected]
www.tetrabiopharma.com

Tags: , , , , ,
Posted in Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary $AERO $CBDS $CGRW $APH.ca $GBLX #CBD #Marijuana

Aurora $ACB.ca and Namaste $N.ca $NXTTF to Complete Strategic Private-Label Software and Patient Referral Agreements $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 7:19 AM on Tuesday, January 2nd, 2018

Nlogo

  • Namaste will provide CanvasRx with a customized, CanvasRx-branded version of NamasteMD
  • Namaste will provide CanvasRx with a two-year exclusivity period for the private label version of NamsteMD.com in Canada

EDMONTON and VANCOUVER, Jan. 2, 2018 – Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Namaste Technologies Inc. (“Namaste”) (CSE: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) today announced the signing of a binding term sheet towards a final Private-Label Software Agreement (“Private Label Agreement”), whereby Namaste will provide Aurora’s wholly-owned subsidiary, CanvasRx Inc. (“CanvasRx”) with a customized version of Namaste’s patient acquisition tool, NamasteMD.com (“NamasteMD”),  as well as desktop and mobile applications for Google Android and Apple iOS platforms. The companies have 30 days to complete a final agreement.

Private Label Agreement

NamasteMD is an online telemedicine platform for patient consultation and registration, bringing together Namaste`s tested technology platform, including certain proprietary authentication technologies, as well as consultation, education and medical document issuance processes. Under the terms of the Private Label Agreement:

  • Namaste will provide CanvasRx with a customized, CanvasRx-branded version of NamasteMD
  • Namaste will provide CanvasRx with a two-year exclusivity period for the private label version of NamsteMD.com in Canada
  • Namaste will initially provide the application for both the Google Android and Apple iOS platforms
  • CanvasRx will require their own doctors and/or nurse practitioners to operate the platform
  • Commercial terms of the agreement are not disclosed
  • In consideration of Aurora’s assistance for the future optimization of NamasteMD, Namaste has issued Aurora 500,000 stock options, exercisable at $3.35 per common share for 48 months, vesting quarterly over 12 months.

Support Services Agreement

In addition, the companies have also signed a non-binding, non-exclusive Letter of Intent to complete a final Consultation & Support Services Agreement (“Consultation Agreement”), whereby Namaste will provide patient referral services to Aurora, where applicable under Canada’s Access to Cannabis for Medical Purposes (“ACMPR”) regulations. Under the terms of the Consultation Agreement:

  • Namaste shall provide certain patient-focused education and strain selection services, as well as assistance in preparing the requisite paperwork (Medical Documentation) for registering patients with Aurora
  • The Agreement is non-exclusive for a one-year term
  • Namaste shall provide the services under the agreement on preferential terms to Aurora
  • Commercial terms of the Consultation Agreement are not disclosed

The agreements further strengthen the strategic ties between the two companies, who already collaborate on eCommerce (sale of Namaste-sourced, curated selection of vaporizers through Aurora website, utilizing Namaste’s technology platform), and the distribution of BC Northern Lights products. Once completed, the new agreements will provide Namaste with recurring revenues through the private label platform, while Aurora will be the only licensed producer able to offer Namaste`s streamlined online patient acquisition platform under its own (CanvasRx) brand.

Management Commentary

“NamasteMD provides an innovative and efficient extension to our industry-leading in-person cannabis counseling and education services provided through CanvasRx,” said Terry Booth, CEO. “The new platform will enable us to extend our industry leading patient care to areas where we currently have no physical presence. This will allow us to leverage the strength of both the CanvasRx and Aurora brands, without having to commit to substantial investments in brick and mortar facilities. Namaste is a trusted partner with whom we already successfully collaborate on two promising initiatives, and we look forward to extending our partnership based on innovation and customer care excellence.”

Sean Dollinger, President and CEO of Namaste added, “We are thrilled to have Aurora, the industry’s most innovative and dynamic Licensed Producer, as our preferred strategic partner. Our drive to innovate meets the cannabis industry`s need for reliable technological solutions to improve operational efficiencies and expand the customer experience. We are very proud to be aligned with Aurora’s team, and look forward to executing on our ongoing collaboration.”

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as “Aurora Mountain”, a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island, and is currently constructing an 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.

In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora’s common shares trade on the TSX under the symbol “ACB”.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany, and has opened new supply channels into emerging markets, including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Boards of Directors

Terry Booth

Sean Dollinger

Chief Executive Officer

Chief Executive Officer

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Aurora and Namaste are under no obligation, and expressly disclaim any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX or CSE, nor their Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange and CSE) accept responsibility for the adequacy or accuracy of this release.

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Aurora $ACB.ca and Namaste $N.ca $NXTTF to Complete Strategic Private-Label Software and Patient Referral Agreements $AERO $CBDS $CGRW $APH.ca $GBLX

World Health Group: Pot’s #CBD Has Health Benefits #Marijuana $MCOA $N.ca $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 4:25 PM on Tuesday, December 19th, 2017
  • Compound found in the cannabis plant is not harmful, has health benefits, and does not have abuse potential, experts at the World Health Organization say.
  • WHO’s Expert Committee on Drug Dependence focused on cannabidiol, or CBD, one of the naturally occurring cannabinoids found in cannabis plants

After reviewing evidence from animal and human studies, the committee concludes that “In humans, CBD exhibits no effects indicative of any abuse or dependence potential.”

Slideshow: Medical Marijuana

1/10

What Is Medical Marijuana?

Medical marijuana is any part of the marijuana plant that you use to treat health problems. People use it to get relief from their symptoms, not to try to get high.

Most marijuana that’s sold legally as medicine has the same ingredients as the kind that people use for pleasure. But some medical marijuana is specially grown to have less of the chemicals that cause feelings of euphoria.

The experts also say that CBD might be able to treat epilepsy (where most research has focused), although results are mixed. Other conditions it might treat are Alzheimer’s disease, Parkinson’s, anxiety, depression, and other maladies. CBD may ease inflammation, provide antioxidants, and relieve pain.

Based on its research, the committee concluded that current information does not call for scheduling of the drug. In the U.S., CBD is a Schedule 1 controlled substance. These are defined as drugs with no medical use and likely to be abused.

Twenty-nine states and Washington, D.C., have legalized the use of marijuana for recreational or medicinal purposes. Other states, including Georgia, have legalized the possession of CBD to treat specific disorders.

It remains a federal crime, however, to have or sell any form of marijuana, including CBD. Despite those federal regulations, CBD is an ingredient in popular products sold over the counter as oils, extracts, supplements, and gum to treat many ailments.

CBD usually is given as a capsule or dissolved in liquid to be taken orally, under the tongue, or as a nasal spray. CBD does not produce the high that another cannabinoid — tetrahydrocannabinol (THC) — does, experts say. In fact, CBD appears to have effects opposite of THC.

The WHO announcement drew a positive response from marijuana advocates and criticism from those who don’t want it to be legal.

The experts produced the report in November, while the WHO announced its conclusions this week. In May, the committee will study cannabis and cannabis-related substances more fully.

Other major studies have shown marijuana and its products can relieve pain, nausea related to cancer treatment, and multiple sclerosis-related muscle spasms. But using cannabis has well-known short-term and long-term health effects, such as learning and coordination problems.

Because federal law makes it a crime to have marijuana and CBD, researchers must pass strict government scrutiny just to study its usefulness.

DEA View of CBD

The conclusion of the WHO flies in the face of the view of the U.S. Drug Enforcement Administration (DEA). It says that CBD must be treated the same as THC and other cannabinoids from a cannabis plant, and it should remain a Schedule I drug.

NORML Response

Marijuana advocates applauded the WHO’s conclusion. “It was terrific to see WHO acknowledge what other scientific research has already stated,” says Justin Strekal, political director of the National Organization for the Reform of Marijuana Laws (NORML).

In an email statement, he adds: “While we are pleased to see the WHO finally acknowledge that absurdity of international restrictions, the continued domestic classification and criminalization of cannabidiol as a Schedule I controlled substance is out of step with both available science and common sense. It is yet another example of the U.S. government placing ideology over evidence when it comes to issues related to the cannabis plant.”

CALM Response

Scott Chipman, Southern California chairman of Citizens Against Legalizing Marijuana (CALM), took issue with the report.

“We need to maintain a strict scientific perspective and protocols when it comes to new drugs,” he says. “We need double-blind studies related to marijuana and all components, research on the harms versus the benefits, identification of the side effects and specific ailments identified through these studies — even for CBD,” he says.

He says some ongoing drug studies of CBD do show promise in treating seizure disorders, but he also sees potential problems with the drugs, along with concerns about contamination and other potential harms with over-the-counter products.

Source: https://www.webmd.com/a-to-z-guides/news/20171215/world-health-group-pots-cbd-has-health-benefits

Tags: , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on World Health Group: Pot’s #CBD Has Health Benefits #Marijuana $MCOA $N.ca $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste Announces LOI With Supreme Pharmaceuticals $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM at 7:30 AM on Monday, December 18th, 2017

 

  • Supreme will supply CannMart ( Namaste ) with a premium range of high quality dried cannabis flower which will be offered in the Company’s medical marketplace
  • Namaste has committed to work with Supreme as a preferred vendor as related to possible branded partnerships
  • The LOI represents further progress for Namaste in securing this supply agreement with one of Canada’s leading producers of premium quality cannabis

 

Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce a Letter of Intent (the “LOI”) with Supreme Pharmaceuticals Inc. (“Supreme”) (TSXV:FIRE) (OTCMKTS:SPRWF). The LOI, signed by Supreme’s wholly owned subsidiary, 7ACRES, and Namaste’s wholly owned subsidiary, Cannmart Inc. (“CannMart”), provides that Supreme will supply CannMart with a premium range of high quality dried cannabis flower which will be offered in the Company’s medical marketplace. Supreme is focused on producing high quality cannabis through a commitment to carefully curated genetics, quality focused cultivation practices and a post-harvest process that includes a 14-day whole plant drying process and hand finishing of each flower.  Under the terms of the LOI, Namaste has committed to work with Supreme as a preferred vendor as related to possible branded partnerships, in addition to supply for Namaste’s in-house branded medical cannabis.  All Supreme cannabis will bear the 7ACRES producer’s mark. Namaste believes that Supreme’s Business to Business (B2B) distribution model fits well with Namaste’s focus on becoming Canada’s leading online retailer for medical cannabis.

Other terms of the LOI include:

  • Purchase orders to be submitted accompanied by terms and conditions governing the purchase and sale of medical cannabis in accordance with Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”)
  • All products sold by 7ACRES to CannMart will be in accordance with ACMPR, 7ACRES Standard Operating Procedures (SOP) and GMP Practices
  • 7ACRES will provide all product descriptions and photography to be used with respect to the sale of 7ACRES products through CannMart
  • CannMart will display 7ACRES trade-mark on all packaging in connection with the sale of any 7ACRES products through CannMart’s website
  • 7ACRES shall be CannMart’s preferred supplier of premium dried cannabis flowers as it relates to celebrity endorsements in partnership with CannMart and Namaste
  • All shipping costs shall be borne by CannMart

The LOI represents further progress for Namaste in securing this supply agreement with one of Canada’s leading producers of premium quality cannabis. Namaste will focus on offering the largest variety of medical cannabis products, sourced from both domestic and international licensed producers. Management feels strongly that the Company’s relationship with Supreme will offer great value with Supreme’s focus on cultivation while Namaste intends to become Canada’s largest online retailer for medical cannabis through the implementation of its telemedicine application, NamasteMD, built as a patient acquisition tool for Namaste to leverage its growing database of Canadian site visitors and offering an extensive variety of medical cannabis products to CannMart’s patients.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to be working with Supreme, who we believe to be one of the top Canadian producers of premium quality cannabis. Our goal is to create an online marketplace for our patients that will offer a variety of products sourced from various licensed producers in Canada and overseas. We believe that our relationship with Supreme will be of significant value as their business model fits well with ours. Thanks to Supreme’s management team for their support and we look forward to launching medical cannabis sales through CannMart in the early new year.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.everyonedoesit.com

www.everyonedoesit.co.uk

Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Small and Micro-Cap Space | Comments Off on Namaste Announces LOI With Supreme Pharmaceuticals $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America $MCOA Launches New hempSMART(TM) Pain Product $MJNA $GRNH $LXRP

Posted by AGORACOM at 8:34 AM on Thursday, December 14th, 2017

 

 

  • Announces the launch of its new personal care product: hempSMART™ Pain.
  • HempSMART Pain Capsules are formulated with 10mg of Full Spectrum, non-psychoactive Cannabidiol (CBD)

 

Escondido, California — (December 14, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp and cannabis company, through its wholly own subsidiary hempSMART™, Inc., announced the launch of its new personal care product: hempSMART™ Pain.

 

HempSMART Pain Capsules are formulated with 10mg of Full Spectrum, non-psychoactive Cannabidiol (CBD) per serving, derived from industrial hemp as the core ingredient, which along with a proprietary blend of other natural ingredients, delivers an all-natural formulation for the temporary relief of minor pain associated with physical activity.

 

Once again, “HempSMART demonstrated its commitment to formulating a safe and synergistic natural personal care product. The hempSMART Pain formula harnesses the natural power of premium CBD, CBG and active terpenes derived from industrial hemp, combined with complimentary botanicals. Our team is focused on the development of premium personal care products for our customers,” said Paula Vetter member of hempSMART’s product development team.

 

“Creating a successful, growing company in our marketplace of direct sales and network marketing depends on delivering products that people need and that make a difference in their lives. The newest addition to the product line, hempSMART Pain was designed and formulated with these goals as the focus. hempSMART Affiliates now have a unique, powerful message to share with potential consumers that could generate new sales for their personal hempSMART businesses, as well as stimulate growth for the company,” commented Tim Altvater, head of affiliate marketing.

 

The CEO of MCOA Donald Steinberg added, “HempSMART Pain adds to our expanding product line. Our formulations are created by the hempSMART product development team to provide our customers with all natural products that contain CBD and other cannabinoids.”

 

About Marijuana Company of America, Inc.
MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

 

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

 

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

 

For more information, please visit the Company’s websites at:

 

MarijuanaCompanyofAmerica.com

hempSMART.com

NewtworkNewsWire/MCOA

Tags:
Posted in Featured, Medical Marijuana Stocks, Small and Micro-Cap Space | Comments Off on Marijuana Company of America $MCOA Launches New hempSMART(TM) Pain Product $MJNA $GRNH $LXRP

« Older Entries
Newer Entries »